Results 91 to 100 of about 6,454 (219)

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

Journal of Sleep Research, EarlyView.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D. Dodd, David J. Murphy, Elise Belaidi, Jean‐Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan   +11 more
wiley   +1 more source

Thirzepatide. A novelty in the treatment of obesity - literature review [PDF]

Introduction Obesity results from a complex interplay of environmental, genetic, and behavioral factors, making it challenging to treat. Globally, the prevalence of obesity has tripled over the past fifty years.
Gmitrzuk, Julita, Jachymek, Anna, Jakubiec, Joanna, Kucharski, Tomasz, Malinka, Zuzanna, Opatowska, Martyna, Piotrowska, Marta, Wiśniewska, Katarzyna   +7 more
core   +1 more source

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion:a review [PDF]

, 2019
The gut-derived incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted after meal ingestion and work in concert to promote postprandial insulin secretion. Furthermore, GLP-1 inhibits glucagon
Bagger, Jonatan I., Bergmann, Natasha C., Christensen, Mikkel B., Knop, Filip K., Lund, Asger, Mathiesen, David S., Vilsbøll, Tina   +6 more
core   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Obesity Reviews, EarlyView.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source

Appendicitis After Initiation of Tirzepatide

Diabetes, Metabolic Syndrome and Obesity
Garrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett ...
Chan G, Ansar M, Klein M
doaj  

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist [PDF]

Treatment for Type 2 Diabetes (T2D) includes incretin hormones, such as glucagon-like peptide-1 (GLP-1) and also glucose-dependent insulinotropic polypeptide (GIP).
Bando, Hiroshi
core  

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Obesity Reviews, EarlyView.
ABSTRACT Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited.
Marie Spreckley, Cara F. Ruggiero, Adrian Brown   +2 more
wiley   +1 more source

Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal of Diabetology
Introduction: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like-peptide-1 receptor agonist (GLP-1 RA), has emerged as a promising option for managing type 2 diabetes.
Mohamed A. Abu-Alsaud, Mohamed Ellebedy, Noha Hammad, Mina I. Lamie, Ahmed F. El-Rawy   +4 more
doaj   +1 more source